Some studies using data from the FDA Adverse Event Reporting System (FAERS) reported a potential increase in cancer risk associated with GLP-1R agonist use (18, 19); however, these findings are not consistently corroborated in retrospective cohort or randomized controlled trials. This evidence concerns the gene GLP1R and cancer.